Paper39236455
Potential mechanisms of rheumatoid arthritis therapy: Focus on macrophage polarization.
Yang X and 5 others. Int Immunopharmacol, 2024. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Potential mechanisms of rheumatoid arthritis therapy: Focus on macrophage polarization. Papers, record 39236455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39236455
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Macrophages | Major topic |
| Antirheumatic Agents | Major topic |
| Humans | |
| Animals | |
| Macrophage Activation | |
| Medicine, Chinese Traditional |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42960261 | Microenvironment-Triggered Sequentially Targeted Micelles for Dual Regulation of Macrophages and Fibroblast-Like Synoviocytes via ROS-Responsive Rg1 Release and HAP-1-Mediated Celastrol Delivery in Rheumatoid Arthritis Therapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42960261 | PubMed |
| 42890560 | Engineering Tripterygium wilfordii-derived exosome-like nanoparticles for targeted therapy in rheumatoid arthritis. | Extracell Vesicles Circ Nucl Acids | 2026 | https://conductscience.org/library/papers/42890560 | PubMed |
| 42332762 | Targeting inflammatory and angiogenic responses by small-molecule kinase inhibitors in a 3D macrophage-containing spheroid model of rheumatoid arthritis synovial tissue. | Arthritis Res Ther | 2026 | https://conductscience.org/library/papers/42332762 | PubMed |
| 41890758 | Nrf2 as a redox checkpoint in autoimmune joint inflammation: microenvironmental redox control across the arthritis spectrum. | Front Immunol | 2026 | https://conductscience.org/library/papers/41890758 | PubMed |
| 41647244 | The Gut Microbiota: Emerging Evidence in Autoimmune and Inflammatory Diseases. | Research (Wash D C) | 2026 | https://conductscience.org/library/papers/41647244 | PubMed |
| 41181606 | Modulating M1/M2 macrophage polarization with plant metabolites: a therapeutic strategy for rheumatoid arthritis. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41181606 | PubMed |
| 40746530 | Exosome circ-CBLB promotes M1 macrophage polarization in rheumatoid arthritis through the TLR3/TRAF3 signaling axis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40746530 | PubMed |
| 39996679 | New Dawn in the Treatment of Rheumatoid Arthritis: Advanced Insight into Polymer Hydrogel Research. | Gels | 2025 | https://conductscience.org/library/papers/39996679 | PubMed |
| 39796166 | Macrophage Polarization: Learning to Manage It 3.0. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39796166 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39236455
GET https://conductscience.org/api/papers/v1/39236455/authors